During the last session, Tenaya Therapeutics Inc. (NASDAQ:TNYA)’s traded shares were 0.71 million. At the end of the trading day, the stock’s price was $5.35, reflecting an intraday gain of 5.11% or $0.26. The 52-week high for the TNYA share is $32.00, that puts it down -498.13 from that peak though still a striking 17.57% gain since the share price plummeted to a 52-week low of $4.41. The company’s market capitalization is $220.05M, and the average intraday trading volume over the past 10 days was 0.11 million shares, and the average trade volume was 135.22K shares over the past three months.
Tenaya Therapeutics Inc. (TNYA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. TNYA has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.76.
Tenaya Therapeutics Inc. (NASDAQ:TNYA) trade information
Tenaya Therapeutics Inc. (TNYA) registered a 5.11% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.11% in intraday trading to $5.35 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 12.16%, and it has moved by -9.01% in 30 days. Based on these gigs, the overall price performance for the year is -71.84%. The short interest in Tenaya Therapeutics Inc. (NASDAQ:TNYA) is 2.46 million shares and it means that shorts have 13.7 day(s) to cover.
The consensus price target of analysts on Wall Street is $27.20, which implies an increase of 80.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $40.00 respectively. As a result, TNYA is trading at a discount of -647.66% off the target high and -180.37% off the low.
Tenaya Therapeutics Inc. (TNYA) estimates and forecasts
Statistics show that Tenaya Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Tenaya Therapeutics Inc. (TNYA) shares have gone down -55.08% during the last six months, with a year-to-date growth rate more than the industry average at 25.85% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 94.30% this quarter and then drop -16.20% in the quarter after that.
While earnings are projected to return -320.00% in 2022.
Tenaya Therapeutics Inc. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Tenaya Therapeutics Inc. (NASDAQ:TNYA)’s Major holders
Tenaya Therapeutics Inc. insiders own 6.27% of total outstanding shares while institutional holders control 91.18%, with the float percentage being 97.29%. Column Group LLC is the largest shareholder of the company, while 91 institutions own stock in it. As of Mar 30, 2022, the company held over 9.4 million shares (or 22.76% of all shares), a total value of $110.74 million in shares.
The next largest institutional holding, with 6.19 million shares, is of FMR, LLC’s that is approximately 14.99% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $72.94 million.
Also, the Mutual Funds coming in first place with the largest holdings of Tenaya Therapeutics Inc. (TNYA) shares are Fidelity Advisor Biotechnology Fund and Fidelity Select Portfolios – Biotechnology. Data provided on May 30, 2022 indicates that Fidelity Advisor Biotechnology Fund owns about 1.38 million shares. This amounts to just over 3.34 percent of the company’s overall shares, with a $9.25 million market value. The same data shows that the other fund manager holds slightly less at 1.26 million, or about 3.06% of the stock, which is worth about $8.47 million.